A portable optical blood coagulation detector is proposed for point-of-care testing for determining prothrombin time (PT). The detector is applicable to sending the results to a computer via wireless transmission. The integrated apparatus comprises an optical module, a signal processing module, and a communication module for directly sensing real-time changes of transmittance during the blood coagulation process. The efficacy of the proposed device was validated with patients' whole blood specimens. Only a small amount of whole blood (approximately 60 μl) is required. The mean relative error of the PT values obtained using the proposed device is 4.8 + 3.5% (less than one second) compared with the PT values obtained using the standard manual PT method (n = 26). The two testing platforms have highly correlated results (r = 0.997, p < 0.001). The proposed device has advantages of portability, ease of operation, real-time results, accuracy, carrying a potential for remote monitoring in the personalized long-distance healthcare industry.
Introduction
Monitoring blood coagulation time is an important routine parameter for patients who suffer from hypertension, cardiovascular, or cerebrovascular diseases and who take some necessary pharmaceuticals which affects homeostasis. Coagulation time can be checked by prothrombin time (PT) test [1] [2] [3] which measures the time of blood coagulation mediated by thromboplastin in the activation of external and common pathways [4] . Thromboplastin in the PT reagent initiates coagulation in a cascade mode in an order of factors, namely VII, X, V, II (prothrombin), and I (fibrinogen), and ends at fibrin cross-link that causes clot formation. PT is widely used to determine various types of deficiency in coagulation factors I, II, V, VII, and X. Prior to surgery, PT is routinely checked to assure proper coagulation function. A prolonged PT might reflect malfunction of the liver [5] , where the coagulant factors are synthesized. The results of PT are necessary in adjustment of optimal dosage in patients receiving anticoagulant treatment such as warfarin to prevent overdose-induced spontaneous hemorrhage [6] . Conventional PT testing is usually performed in central laboratories of hospitals. For patients who have no convenient access to hospitals, a portable point-of-care testing (POCT) blood coagulation detector allows the monitoring of blood coagulation at a near-patient site. Moreover, the data can be transmitted wirelessly to a computer, which then possibly send it over the internet to healthcare workers in hospitals or local medical organizations [7] . It saves patients' time and helps doctors immediately and efficiently obtain test results. Therefore, the development of a portable self-monitoring blood coagulation detector is of great benefit to personalized longdistance healthcare.
PT testing can be performed using methods based on several principles, such as electric impedance methods [8] [9] [10] [11] , piezoelectric quartz crystal methods [12, 13] , and optical methods [14, 15] . Optical-based technology is utilized in the present study because optical devices suitable for POCT are relatively versatile, inexpensive, and easy to obtain, and can provide highly sensitive and accurate measurements. As the fibrin clot forms, light penetrability through the blood sample decreases. A light-emitting diode (LED) is used as a low-power light source at the top of the detection area, and a photoresistor is fixed beneath the blood sample to transform the variations of light penetrability into analogy electronic signals, which are then converted into digital signals. Finally, the signals are modulated and transmitted via Bluetooth (BT) to a computer. Figure 1 shows a system block diagram of the proposed portable blood coagulation detector for a long-distant health care network. The detector is capable of detecting uncentrifuged whole blood specimens directly without plasma preparation, and thus the turnaround time is below 5 minutes and the required sample volume is 60 μL. The system size and power consumption are significantly reduced. However, direct detection using whole blood samples has several challenges. For instance, the whole blood components are complicated and heterogeneous due to the presence of substantial amounts of blood cells and plasma proteins [3, 15] . These impurities significantly affect light penetrability and therefore affect the measurement accuracy. The proposed device overcomes this interference by adding an analog filter and by increasing the signal-to-noise ratio by increasing sample concentration and optimizing micro-channel thickness. 
Materials and methods

Overview and description of proposed system
The proposed portable blood coagulation detector integrates a micro-channel, an optical source and detector, a receiving module, a display module, a data transmission module, a timer, and a power supply. Figure 2 shows a block diagram of the whole circuit.
The blood sample is loaded onto glass or polydimethylsiloxane (PDMS) through a 10 (L) × 6 (W) × 0.1-0.2 (H) mm 3 micro-channel, as shown in Fig. 3 , to reduce reagent consumption and shorten the time required for blood distribution and reagent mixing. A strong green LED (TY-HG1-4) is applied as the optical source and a photoresistor (SR-5) is used for optical detection. A micro-controller (TI MSP430F149, Texas Instruments, Dallas, TX, USA) [16] with an internal analog-to-digital converter (ADC) is used as the micro-processor. The microprocessor features a super low-powered micro-control unit (MCU) and a built-in 12-bit high-speed ADC, which significantly reduces the total area on the printed circuit board (PCB) and total power consumption. Due to the low power loss and consumption, this microprocessor is suitable for embedded systems for portable medical devices. The display module (LCD1602) is used to display the time and voltage values, allowing the test results to be viewed immediately. Wireless data transmission is implemented using a BT chip (HL-MD08R-C2A, Hotlife Tech., Taipei 
Circuit design
The principle of optical detection follows the BeerLambert law:
where A is the absorbance, c is the molar absorption coefficient, l is the distance which light passes through the material, and m is the concentration of the material. The light transmittance through the sampled whole blood is altered as coagulation process starts, changing the intrinsic optical properties. The changes in the light transmittance signal through the whole process are expected to be small. In order to obtain the largest absorption coefficient of blood, a strong green LED (TY-HG1-4), with wavelengths in the range of 540 to 570 nm [17] , is used as the light source. A cadmium sulfide (CdS, SR-5) photoresistor is used as an optical detector in the system due to its wide detection range. A Wheatstone bridge is used to measure the voltage across the photoresistor in response to the variation of luminous intensity. The resistance in the arms of the bridge was initially fine-tuned to the essential working range. Figure 4 shows the electrical bridge and analog amplifier circuits. To reduce the thermal and background noise from the circuits and surrounding environment, the output voltage from the Wheatstone bridge was designed to pass through a fourth-order low-pass filter (LPF), composed of two cascaded second-order Butterworth LPFs. The LPF in the system requires resistances of R 13 = R 14 = R 15 = R 16 = 63 kΩ and capacitances of C 3 = C 4 = C 5 = C 6 = 100 nF. An active twin-T notch filter is applied to remove 60-Hz spur noise from the power supply. The optimized system can detect effective signals with a bandwidth of approximately 25 Hz, which preserves the light transmittance profile due to blood coagulation and suppresses most unwanted interference. Most biological signals vary slowly and are counted as low-frequency components, so signals with a frequency of over 25 Hz were considered interference. Information of blood coagulation PT was reserved since most of the sampling signal energy was located in frequencies below 15 Hz. After the fast Fourier transform (FFT) was applied, the frequency range distribution was analyzed. The signals prior to filtering were centered at a low frequency. The LPF was thus used to allow signals with frequencies of below 25 Hz to pass through. As shown in Fig. 5(a) , the signals became more stable and less noisy after the high-frequency noise was filtered out. As shown in Fig. 5(b) , after the fourth-order LPF and FFT, the power at the high-frequency noise was suppressed effectively. As the high-frequency noise was suppressed, the PT signals (below 25 Hz) were easily determined. Notably, the signals had an offset after LPF filtration, so a constant voltage offset was added to reduce the offset. Suppressing high-frequency interference is crucial when determining the PT point because noise at high frequency might be enlarged after the differentiation operation. It is thus critical to adopt filtering to detect whole blood PT. 
Implementation and measurement setup
Ambient control is important in biological measurement. In the experiment, an acrylic black box was used to reduce the background light. The mean room temperature was ~27 °C during the test period. Unlinked anonymous human whole blood samples were taken from the Central Hematology Laboratory of National Cheng Kong University Hospital, which was approved by the local Institutional Review Board (IRB). The thromboplastin reagent (15 μl, Dade Innovin) was added to initiate blood coagulation, and the changes of light transmittance within 3 minutes were recorded and transmitted to a computer. These results were then compared with the PT results simultaneously measured using the standard manual method [1] . A 6 1 / 2 digital multimeter (M3500A, Picotest, USA) was used to record gauge voltage values along with the fabricated devices in parallel.
Results and discussion
The experimental results were used to validate the functionality of the proposed PT device and estimate the optimal parameters. The ratio of the whole blood sample and thromboplastin reagent was adjusted from 2:1 to 4:1 to increase the red-color density in order to precisely determine the turning point of transmittance changes. Figures 6 and 7 show plots of measured voltage as a function of time in the coagulation process from the proposed detector and digital multi-meter, respectively. The turning point of the first-order differential curve of the signal during coagulation indicates the PT value [18] . As shown in Fig. 6 , the PT turning points were compared with variations in the thickness of the micro-channel and the blood-to-thromboplastin-reagent ratio (vol:vol). The results show that the PT turning point was prominent with the 100-or 200-µm-thick micro-channel and a 4:1 blood-to-reagent ratio. The proposed system determines the PT values as 38 s which is close to the time verified by the standard manual method. With a 100-µm-thick micro-channel and a 2:1 ratio, the turning point was undetectable, implying that the signal was below the detection limit due to the existence of heavy noise or interference. The turning points can be made more obvious by using the optimal thickness of the micro-channel and optimal concentration of the mixture (blood and reagent). As shown in Fig. 7(a) , the uncoagulated blood samples flowed into the micro-channel, covered the detection window within 10 s and displayed an upward curve until it reached a plateau, which indicating that no coagulation occurs. With a blood sample undergoing coagulation, as shown in Fig. 7(b) , it took 8 to 10 s to cover the detection area after the thromboplastin reagent had been mixed with the blood sample (s) and then loaded to the detector. Once the blood covered the micro-channel entirely, the measured voltage increased and then declined at the turning point, representing blood coagulation starts. As the blood sample began the coagulation process, the light transmittance started to decrease. A first-order differential transformation was then performed to obtain the exact PT values. For instance, the first-order differential curve of coagulation in Fig. 7(c) shows that there is a maximum velocity point at 52 s, which means the time of most stimulating coagulation action, indicating the PT, as defined in [4] . Measurement results from the first-order differential curves are close to the PT values obtained using the manual method. In Fig. 7(a) , the blood samples without coagulants produced signal curves that had no turning points. In Fig. 7(b) , the dashed line represents the reference results obtained using the 6 1 / 2 digital multimeter, which is a highly precise instrument and thus served as a standard measurement. The curves obtained using the proposed detector are close to the reference curves, except for a slight vertical offset difference, which may not affect the determination of PT. The normal PT ranges from 10 to 13 s, which quick dynamics have more difficulties for an accurate detection than do the prolonged PTs. The baseline signal caused by the sample entering the micro-channel may affect the turning point of the blood coagulation curve. Therefore, it is not feasible to determine normal-range PT if the time required for the blood/ reagent mixture to fill the micro-channel is more than 4 s. In the POCT, the blood/reagent mixtures were loaded quickly to ensure complete coverage of the detection area in the microchannel within 4 s. As shown in Fig. 8(a) , the turning point was not obvious for a PT value of 10.7 s due to the overlap of the interference from sample filling and the signal from blood coagulation. Therefore, detection by turning point to determine PT may not feasible in some cases. With first-order differentiation, the PT can be determined according to the maximum acceleration point. As shown in Fig. 8(b) , the turning point is clear for a PT of 11.7 s, which is one second longer than that of the sample in Fig. 8(a) . This may be due to the process of sample loading and covering the detection area completes before blood coagulation begins, so the filling noise does not interfere with the PT signal. Table 1 summarizes the results of the proposed device with those of the standard manual method. Fifteen samples with normal PT (ranging from 11 to 12 s) and 11 samples with prolonged PT (ranging from 18 to 52 s) were recruited. Compared to the PT values obtained using the standard manual method, the relative errors of the PT values obtained using the proposed device were 5.1 + 3.3% for the normal PTs and 4.5 + 3.9% for the prolonged PTs. A relative error of 4.8 + 3.5% and a difference of less one second (0.9 + 0.7 s) was observed for the 26 tested samples. As shown in Fig. 9 , the PT results using the proposed device and the manual method are highly correlated (n = 26, r = 0.997, p < 0.001).
Conclusion
A portable optical detector for blood coagulation was designed and implemented. The proposed device overcomes the challenges due to complexity and impurities by using a small amount of uncentrifuged whole blood. The PT value is determined from the maximum acceleration point of the changes of light transmittance during thromboplastin-induced whole blood coagulation. The optical-based coagulation device was validated as an accurate and sensitive PT detector with patient samples with either normal or prolonged PT cases. The mean relative error of the PT results obtained from the proposed device was less than 5% or 1 s compared with the results obtained using the standard manual PT method. The results from the proposed device are significantly correlated with those obtained using the standard manual PT method (n = 26, r = 0.997, p < 0.001). The proposed portable blood coagulation detector is efficient and accurate for POCT, and thus holding a potential for wirelessly transfer via Internet topersonalized long-distance health care prospectively. POCT PT (s) Figure 9 . Comparison of PT values obtained using proposed device and standard manual method. The results from proposed device are highly correlated with those from manual PT method (n = 26, r = 0.997, p < 0.001).
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